Scott Gottlieb tempts the FDA's fiercest critics with his leap onto Pfizer's board of directors
The next chapter of Scott Gottlieb’s career will be played out in the inner sanctums of Big Pharma — forever reinforcing the FDA’s critics of the revolving door between the agency and the industry.
After the market closed on Thursday, Pfizer — the biggest of the big — said that the ex-commissioner had been elected to its board of directors. That comes on top of his roles as a special venture partner at New Enterprise Associates and regular commentator on all things drug-related for the conservative American Enterprise Institute, where he’s become a high-profile figure.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 60,200+ biopharma pros reading Endpoints daily — and it's free.